A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback